Hims & Hers Hits Oversold Territory as Novartis Lawsuit Weighs, But Analysts See Nearly 150% Upside

Hims & Hers stock has dropped 75.5% from its May 2025 high of $64.65, largely driven by a February 2026 Novo Nordisk lawsuit.
Despite the sell-off, Reddit sentiment for
$HIMS is bullish (0.575), and the stock ranks #3 among trending tickers on Tendie.bot.
Analysts see nearly 150% upside from current levels, pointing to the company's strong core telehealth and wellness business beyond GLP-1s.

Hims & Hers Health (

$HIMS) has plummeted 75.50% from its May 2025 all-time high of $64.65, becoming one of the most-discussed stocks in retail investor circles on Monday. The dramatic sell-off follows a November 2025 lawsuit from Novo Nordisk, which alleges that the telehealth company unlawfully markets unapproved versions of semaglutide, the active ingredient in Ozempic and Wegovy.

Why Reddit Is Watching HIMS

Despite the brutal price action,

$HIMS climbed to #3 on Tendie.bot's trending ticker rankings on February 24, driven by 5 posts and 275 comments across Reddit. Retail sentiment remains solidly bullish with a score of 0.575, even as the stock sits deep in oversold territory with a relative strength index (RSI) of 16.87.

Much of the discussion on r/wallstreetbets and related investing subreddits centers on whether the GLP-1 headwind is overblown. Retail investors are pointing to the company's other high-growth segments—telehealth for hair thinning, sexual health, and dermatology—as reasons the stock might be deeply undervalued at current levels.

HIMS

The News Context: Analysts See 150% Upside

A February 24 analysis from Investing.com highlights the disconnect between

$HIMS's market price and analyst expectations. Despite the 75% decline, the average 12-month price target from analysts stands at $39.32, implying nearly 150% upside. The company is also expected to report record quarterly revenue of $619 million in its upcoming earnings report.

The bull case rests on the idea that the Novo Nordisk lawsuit, while serious, may not cripple

$HIMS's broader business. The company's core telehealth platform continues to grow, and its non-GLP-1 offerings in high-margin categories like hair loss and sexual health supplements could provide a floor for revenue growth.

What to Watch Next

Earnings reaction: The market will closely watch how
$HIMS trades after its record revenue report on February 23.
GLP-1 legal developments: Any resolution or update in the Novo Nordisk lawsuit could be a major catalyst either direction.
RSI bounce: With the stock deeply oversold, some traders on Reddit are betting on a mean-reversion rally in the near term.

Subscribe to Tendie.bot for more market recaps.